Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Satellos Bioscience ( (TSE:MSCL) ) has provided an announcement.
Satellos Bioscience reported positive results from its Phase 1b study of SAT-3247 in adults with Duchenne muscular dystrophy, demonstrating safety and improved grip strength. The company plans to initiate a follow-up study and a global Phase 2 trial in children with DMD. Financially, Satellos ended Q2 2025 with $52.1 million in cash, experiencing a net loss due to increased R&D and administrative expenses.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$1.20 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on TSE:MSCL Stock
According to Spark, TipRanks’ AI Analyst, TSE:MSCL is a Neutral.
Satellos Bioscience faces challenges typical of early-stage biotech companies, including no revenue and reliance on financing to sustain operations. Technical indicators suggest a bearish momentum. However, positive corporate developments, such as clinical trial progress and increased financing, provide a potential upside if successful commercialization ensues.
To see Spark’s full report on TSE:MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing life-improving medicines to treat degenerative muscle diseases. The company is working on innovative treatments, such as SAT-3247, aimed at rebuilding muscle and improving strength, particularly for conditions like Duchenne muscular dystrophy (DMD).
Average Trading Volume: 151,867
Technical Sentiment Signal: Sell
Current Market Cap: C$105.8M
For an in-depth examination of MSCL stock, go to TipRanks’ Overview page.